US008980257B2

(12) **United States Patent**
Kaneda et al.

(10) **Patent No.: US 8,980,257 B2**
(45) **Date of Patent: Mar. 17, 2015**

(54) **ANTIBODY BEING CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING GROWTH-SUPPRESSING ACTIVITY ON CANCERS HAVING RAS GENE MUTATION**

(75) Inventors: **Makoto Kaneda**, Ina (JP); **Yoshihiro Fujii**, Ina (JP); **Yoshihiro Hayata**, Ina (JP); **Yoshiro Kishi**, Ina (JP); **Ichiro Yahara**, Ina (JP)

(73) Assignee: **Medical & Biological Laboratories Co., Ltd.**, Aichi (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/698,420**

(22) PCT Filed: **May 17, 2011**

(86) PCT No.: **PCT/JP2011/061347**

§ 371 (c)(1),
(2), (4) Date: **Jan. 30, 2013**

(87) PCT Pub. No.: **WO2011/145629**

PCT Pub. Date: **Nov. 24, 2011**

(65) **Prior Publication Data**

US 2013/0131322 A1 May 23, 2013

(30) **Foreign Application Priority Data**

May 18, 2010 (JP) 2010-114460

(51) **Int. Cl.**

A61K 39/00	(2006.01)
A61K 39/395	(2006.01)
C07K 16/00	(2006.01)
C07K 16/18	(2006.01)
C07K 16/24	(2006.01)
C12N 15/00	(2006.01)
C12N 15/09	(2006.01)
C12N 15/11	(2006.01)
C12N 15/13	(2006.01)
C12N 15/63	(2006.01)
C12N 5/10	(2006.01)
C12N 5/16	(2006.01)
C12N 5/18	(2006.01)
C12N 5/20	(2006.01)
C12N 5/22	(2006.01)
C12N 5/24	(2006.01)
C12N 5/26	(2006.01)
C12N 5/28	(2006.01)
C07K 16/22	(2006.01)
C07K 14/495	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/22*** (2013.01); ***C07K 14/495*** (2013.01); *A61K 2039/505* (2013.01); *C07K 2317/24* (2013.01); *C07K 2317/76* (2013.01)

USPC **424/130.1**; 424/133.1; 424/135.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 530/387.1; 530/387.3; 530/387.9; 530/388.1; 530/388.15; 530/388.23; 435/69.1; 435/325; 435/326; 435/328; 435/331; 435/335; 435/252.3; 435/254.11; 435/320.1; 536/23.1; 536/23.5; 536/23.53

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,190,858	A	3/1993	Sorvillo et al.	
2013/0131322	A1 *	5/2013	Kaneda et al.	530/388.24

OTHER PUBLICATIONS

Paul, Fundamental Immunology, 1993, 3rd edition, Raven Press, NY, pp. 292-295.*
Casset et al. (Biochem Biophys Res Comm. 2003; 307:198-205).*
MacCallum et al. (J Mol Biol. 1996; 262:732-745).*
Vajdos et al. (J Mol Biol. 2002; 320(2):415-428).*
Holm et al. (Mol Immunol. 2007; 44(6):1075-1084).*
Chen et al. (J Mol Biol. 1999; 293:865-881).*
Eisen et al., 2014, Curr. Oncol. Rep. 16(370):1-6.*
A. B. Roberts et. al, "Isolation From Murine Sarcoma Cells of Novel Transforming Growth Factors Potentiated by EGF", Nature, Feb. 4, 1982, p. 417-419. vol. 295.
Alain B. Schreiber et. al, "Transforming Growth Factor-α: A More Potent Angiogenic Mediator Than Epidermal Growth Factor", Science, 1986, pp. 1250-1253, vol. 232.
Alberto Bardelli et. al, "Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer", Journal of Clinical Oncology, Biology of Neoplasia, Mar. 1, 2010, pp. 1254-1261, vol. 28, No. 7.
Ami Citri et. al,"EGF-ERBB Signalling: Towards the Systems Level", Nature Reviews, Molecular Cell Biology , Jul. 2006, pp. 505-516, vol. 7.
Amir Onn et. al, "Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung cancer", Clinical Cancer Research, Jan. 1, 2004, pp. 136-143, vol. 10.
Anita B. Roberts et. al, "Transforming Growth Factors: Isolation of Polypeptides From Virally and Chemically Transformed Cells by Acid/Ethanol Extraction", Cell Biology, Proc. Natl. Acad. Sci. USA , Jun. 1980, pp. 3494-3498, vol. 77, No. 6.

(Continued)

Primary Examiner — Elizabeth C Kemmerer
(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC

(57) **ABSTRACT**

It has been found out that among antibodies showing reactivity with wild type TGF-α, antibodies less reactive with G79A-substituted TGF-α have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.

19 Claims, 26 Drawing Sheets
(2 of 26 Drawing Sheet(s) Filed in Color)